Out-of-Pocket Costs and Payer Types for Buprenorphine Among US Youth Aged 12 to 19 Years.
作者信息
Terranella Andrew, Guy Gery, Strahan Andrea, Mikosz Christina
机构信息
Division of Overdose Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.
出版信息
JAMA Pediatr. 2023 Oct 1;177(10):1096-1098. doi: 10.1001/jamapediatrics.2023.2376.
Abstract
摘要
相似文献
1
Out-of-Pocket Costs and Payer Types for Buprenorphine Among US Youth Aged 12 to 19 Years.美国12至19岁青少年丁丙诺啡的自付费用和支付方类型
JAMA Pediatr. 2023 Oct 1;177(10):1096-1098. doi: 10.1001/jamapediatrics.2023.2376.
2
Proliferation of Cash-Only Buprenorphine Treatment Clinics: A Threat to the Nation's Response to the Opioid Crisis.仅提供丁丙诺啡治疗的诊所激增：对国家应对阿片类药物危机的威胁。
Am J Public Health. 2019 Mar;109(3):393-394. doi: 10.2105/AJPH.2018.304899.
3
Association Between Cost-Sharing and Buprenorphine Prescription Abandonment.费用分担与丁丙诺啡处方放弃的关联。
J Gen Intern Med. 2024 Sep;39(12):2160-2168. doi: 10.1007/s11606-024-08819-2. Epub 2024 Jun 18.
4
Buprenorphine Out-of-Pocket Costs and Discontinuation in Privately Insured Adults With Opioid Use Disorder.丁丙诺啡自付费用与患有阿片类物质使用障碍的私人保险成年人停药情况
JAMA Intern Med. 2023 Sep 1;183(9):1023-1026. doi: 10.1001/jamainternmed.2023.2826.
5
The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence.预先授权对马萨诸塞州医疗补助计划中阿片类药物依赖受益人的丁丙诺啡剂量、复发率和成本的影响。
Health Serv Res. 2014 Dec;49(6):1964-79. doi: 10.1111/1475-6773.12201. Epub 2014 Jul 9.
6
Trends in Out-of-Pocket Costs for and Characteristics of Pharmacy-Dispensed Naloxone by Payer Type.按支付方类型划分的药房配给纳洛酮的自付费用趋势及特征
JAMA. 2024 Feb 27;331(8):700-702. doi: 10.1001/jama.2023.26969.
7
Real-world changes in US health system hospital-based services following treatment with a prescription digital therapeutic for opioid use disorder.美国医疗系统中基于医院的服务在使用处方数字治疗药物治疗阿片类药物使用障碍后的实际变化。
Hosp Pract (1995). 2021 Dec;49(5):341-347. doi: 10.1080/21548331.2021.1956256. Epub 2021 Aug 6.
8
Management of opioid-dependent patients: comparison of the cost associated with use of buprenorphine/naloxone or methadone, and their interactions with concomitant treatments for infectious or psychiatric comorbidities.阿片类药物依赖患者的管理：丁丙诺啡/纳洛酮或美沙酮使用相关成本的比较，以及它们与感染性或精神性合并症的伴随治疗之间的相互作用。
Adicciones. 2015 Sep 15;27(3):179-89.
9
Pattern of Buprenorphine Treatment Retention Among Youth Aged 10 to 18 Years-US, 2015 to 2021.2015年至2021年美国10至18岁青少年丁丙诺啡治疗保留模式
JAMA Pediatr. 2024 Sep 1;178(9):940-942. doi: 10.1001/jamapediatrics.2024.2502.
10
Trends in Out-of-Pocket Costs for and Characteristics of Pharmacy-Dispensed Buprenorphine Medications for Opioid Use Disorder Treatment by Type of Payer, 2015 to 2020.2015 年至 2020 年按支付类型划分的用于治疗阿片类药物使用障碍的药房配给丁丙诺啡药物的自付费用和特征趋势。
JAMA Netw Open. 2023 Feb 1;6(2):e2254590. doi: 10.1001/jamanetworkopen.2022.54590.
引用本文的文献
1
Prevention and Management of Opioid use Disorder and Overdose in Adolescents and Young Adults.青少年和青年阿片类药物使用障碍及过量用药的预防与管理
Curr Psychiatry Rep. 2025 Sep 12. doi: 10.1007/s11920-025-01638-0.
2
Adolescent Treatment Landscape of Depression, Suicidality, and Substance Use Disorder in the US.美国青少年抑郁症、自杀倾向及物质使用障碍的治疗现状
JAMA Health Forum. 2025 Aug 1;6(8):e252647. doi: 10.1001/jamahealthforum.2025.2647.
3
Enhancing Outcomes in Opioid Use Disorder Treatment: An Economic Evaluation of Improving Medication Adherence for Buprenorphine Through Blister-Packaging.改善阿片类物质使用障碍治疗效果：通过泡罩包装提高丁丙诺啡药物依从性的经济学评估
Subst Abuse Rehabil. 2024 Oct 22;15:209-222. doi: 10.2147/SAR.S484831. eCollection 2024.
4
Use of in-network insurance benefits is critical for improving retention in telehealth-based buprenorphine treatment.使用网络内保险福利对于提高基于远程医疗的丁丙诺啡治疗的留存率至关重要。
Health Aff Sch. 2024 Jan 30;2(3):qxae009. doi: 10.1093/haschl/qxae009. eCollection 2024 Mar.
5
Sources of nonmedically used prescription psychotherapeutic drugs using real-world data from adolescents and adults assessed for substance use treatment--2014-2022.利用 2014-2022 年接受物质使用治疗评估的青少年和成年人的真实世界数据，评估非医疗使用处方精神治疗药物的来源。
Res Social Adm Pharm. 2024 Feb;20(2):209-214. doi: 10.1016/j.sapharm.2023.10.014. Epub 2023 Oct 29.
Zotero 插件